Edward Stites, MD, PhD
Laboratory Medicine
Biography
Edward Stites, MD, PhD, is a laboratory medicine specialist who applies both experimental and computational methods to diagnose and study diseases, with a particular focus on cancer.
Dr. Stites investigates how certain proteins, known as RAS proteins, help control cell growth and may contribute to tumor development. As an associate professor of laboratory medicine at Yale School of Medicine, he explores mathematical approaches to better understand disease processes.
He completed his medical training from the University of Virginia and pursued residency in pathology at Washington University School of Medicine.
Titles
- Associate Professor of Laboratory Medicine and Pathology
Education & Training
- Postdoctoral FellowWashington University School of Medicine (2016)
- ResidentWashington University School of Medicine (2015)
- Randy Pausch ScholarTranslational Genomics Research Institution (2012)
- MDUniversity of Virginia (2010)
- PhDUniversity of Virginia, Biophysics (2008)
- BSUniversity of Kentucky, Mathematics (1998)
Additional Information
Honors & Recognitions
- New Innovator Award (DP2): National Institutes of Health Director's Common Fund (2020)
- Career Development Award: Department of Defense (2020)
- Lung Cancer Discovery Award: American Lung Association (2020)
- Young Investigator Award: Melanoma Research Alliance (2018)
- Career Development Award: National Cancer Institute (2017)
Professional Service
- Forbeck Foundation (2024 - Present): Member
Publications
- Arun A, Liarakos D, Mendiratta G, Kim J, Goshua G, Olson P, Stites E. Integrating epidemiology and genomics data to estimate the prevalence of acquired cysteine drug targets in the U.S. cancer patient population. The Pharmacogenomics Journal 2025, 25: 5. PMID: 40044654, DOI: 10.1038/s41397-025-00364-3.
- Trogdon M, Abbott K, Arang N, Lande K, Kaur N, Tong M, Bakhoum M, Gutkind J, Stites E. Systems modeling of oncogenic G-protein and GPCR signaling reveals unexpected differences in downstream pathway activation. Npj Systems Biology And Applications 2024, 10: 75. PMID: 39013872, PMCID: PMC11252164, DOI: 10.1038/s41540-024-00400-1.
- Mendiratta G, Liarakos D, Tong M, Ito S, Ke E, Goshua G, Stites E. Cancer research is not correlated with driver gene mutation burdens. Med 2024, 5: 832-838.e4. PMID: 38908369, DOI: 10.1016/j.medj.2024.05.013.
- Stites E. The Abundance of KRAS and RAS Gene Mutations in Cancer. Methods In Molecular Biology 2024, 2797: 13-22. PMID: 38570449, DOI: 10.1007/978-1-0716-3822-4_2.
- Ito S, Pandya A, Hauser R, Krishnamurti L, Stites E, Tormey C, Krumholz H, Hendrickson J, Goshua G. Decreasing alloimmunization‐specific mortality in sickle cell disease in the United States: Cost‐effectiveness of a shared transfusion resource. American Journal Of Hematology 2024, 99: 570-576. PMID: 38279581, DOI: 10.1002/ajh.27211.
- Mendiratta G, Stites E. Theoretical analysis reveals a role for RAF conformational autoinhibition in paradoxical activation. ELife 2023, 12: e82739. PMID: 37823369, PMCID: PMC10627510, DOI: 10.7554/elife.82739.
- Baglaenko Y, Wagner C, Bhoj V, Brodin P, Gershwin M, Graham D, Invernizzi P, Kidd K, Korsunsky I, Levy M, Mammen A, Nizet V, Ramirez-Valle F, Stites E, Williams M, Wilson M, Rose N, Ladd V, Sirota M. Making inroads to precision medicine for the treatment of autoimmune diseases: Harnessing genomic studies to better diagnose and treat complex disorders. Cambridge Prisms Precision Medicine 2023, 1: e25. PMID: 38550937, PMCID: PMC10953750, DOI: 10.1017/pcm.2023.14.
- Stites E. Computational Random Mutagenesis to Investigate RAS Mutant Signaling. Methods In Molecular Biology 2023, 2634: 329-335. PMID: 37074586, PMCID: PMC10530643, DOI: 10.1007/978-1-0716-3008-2_15.
- McFall T, Trogdon M, Guizar A, Langenheim J, Sisk-Hackworth L, Stites E. Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP. Npj Precision Oncology 2022, 6: 86. PMID: 36418474, PMCID: PMC9684405, DOI: 10.1038/s41698-022-00329-w.
- Stites E, Paskvan K, Kato S. Therapeutic Targeting of RAS Mutant Cancers. 2022 DOI: 10.1017/9781009064828.
- Mendiratta G, Jones M, Stites E. How often is each gene mutated within the cancer patient population? Molecular & Cellular Oncology 2022, 9: 2065176. PMID: 35529901, PMCID: PMC9067461, DOI: 10.1080/23723556.2022.2065176.
- McFall T, Stites E. Identification of RAS mutant biomarkers for EGFR inhibitor sensitivity using a systems biochemical approach. Cell Reports 2021, 37: 110096. PMID: 34910921, PMCID: PMC8867612, DOI: 10.1016/j.celrep.2021.110096.
- Mendiratta G, Ke E, Aziz M, Liarakos D, Tong M, Stites E. Cancer gene mutation frequencies for the U.S. population. Nature Communications 2021, 12: 5961. PMID: 34645806, PMCID: PMC8514428, DOI: 10.1038/s41467-021-26213-y.
- Stites E. Mathematical Modeling to Study KRAS Mutant-Specific Responses to Pathway Inhibition. Methods In Molecular Biology 2021, 2262: 311-321. PMID: 33977486, PMCID: PMC8639139, DOI: 10.1007/978-1-0716-1190-6_19.
- Kato S, McFall T, Takahashi K, Bamel K, Ikeda S, Eskander R, Plaxe S, Parker B, Stites E, Kurzrock R. KRAS‐Mutated, Estrogen Receptor‐Positive Low‐Grade Serous Ovarian Cancer: Unraveling an Exceptional Response Mystery. The Oncologist 2021, 26: e530-e536. PMID: 33528846, PMCID: PMC8018312, DOI: 10.1002/onco.13702.
- McFall T, Schomburg N, Rossman K, Stites E. Discernment between candidate mechanisms for KRAS G13D colorectal cancer sensitivity to EGFR inhibitors. Cell Communication And Signaling 2020, 18: 179. PMID: 33153459, PMCID: PMC7643456, DOI: 10.1186/s12964-020-00645-3.
- Kato S, Kim K, Lim H, Boichard A, Nikanjam M, Weihe E, Kuo D, Eskander R, Goodman A, Galanina N, Fanta P, Schwab R, Shatsky R, Plaxe S, Sharabi A, Stites E, Adashek J, Okamura R, Lee S, Lippman S, Sicklick J, Kurzrock R. Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy. Nature Communications 2020, 11: 4965. PMID: 33009371, PMCID: PMC7532150, DOI: 10.1038/s41467-020-18613-3.
- Stites EC, Wilen CB. The Interpretation of SARS-CoV-2 Diagnostic Tests. Med 2020, 1: 78-89. PMID: 32864639, PMCID: PMC7441939, DOI: 10.1016/j.medj.2020.08.001.
- Mendiratta G, McFall T, Stites E. Abstract 5509: Breaking the paradox breakers - RAF inhibitor mechanisms. Cancer Research 2020, 80: 5509-5509. DOI: 10.1158/1538-7445.am2020-5509.
- McFall T, Stites E. Abstract 37: Computational analysis of the KRAS G13D colorectal cancer response to EGFR inhibition with an alternatively parameterized model. Clinical Cancer Research 2020, 26: 37-37. DOI: 10.1158/1557-3265.advprecmed20-37.
- Stites E, McFall T. A Biophysical Basis for a Targeted Therapy Exceptional Responder KRAS Mutation. Biophysical Journal 2020, 118: 451a. DOI: 10.1016/j.bpj.2019.11.2515.
- McFall T, Stites E. A mechanism for the response of KRASG13D expressing colorectal cancers to EGFR inhibitors. Molecular & Cellular Oncology 2020, 7: 1701914. PMID: 32158916, PMCID: PMC7051129, DOI: 10.1080/23723556.2019.1701914.
- McFall T, Diedrich J, Mengistu M, Littlechild S, Paskvan K, Sisk-Hackworth L, Moresco J, Shaw A, Stites E. A systems mechanism for KRAS mutant allele–specific responses to targeted therapy. Science Signaling 2019, 12 PMID: 31551296, PMCID: PMC6864030, DOI: 10.1126/scisignal.aaw8288.
- Erickson KE, Rukhlenko OS, Shahinuzzaman M, Slavkova KP, Lin YT, Suderman R, Stites EC, Anghel M, Posner RG, Barua D, Kholodenko BN, Hlavacek WS. Modeling cell line-specific recruitment of signaling proteins to the insulin-like growth factor 1 receptor. PLOS Computational Biology 2019, 15: e1006706. PMID: 30653502, PMCID: PMC6353226, DOI: 10.1371/journal.pcbi.1006706.
- Rauen K, Schoyer L, Schill L, Stronach B, Albeck J, Andresen B, Cavé H, Ellis M, Fruchtman S, Gelb B, Gibson C, Gripp K, Hefner E, Huang W, Itkin M, Kerr B, Linardic C, McMahon M, Oberlander B, Perlstein E, Ratner N, Rogers L, Schenck A, Shankar S, Shvartsman S, Stevenson D, Stites E, Stork P, Sun C, Therrien M, Ullian E, Widemann B, Yeh E, Zampino G, Zenker M, Timmer W, McCormick F. Proceedings of the fifth international RASopathies symposium: When development and cancer intersect. American Journal Of Medical Genetics Part A 2018, 176: 2924-2929. PMID: 30302932, PMCID: PMC6312476, DOI: 10.1002/ajmg.a.40632.
- Stites E, Shaw A. Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors. CPT Pharmacometrics & Systems Pharmacology 2018, 7: 342-351. PMID: 29484842, PMCID: PMC5980551, DOI: 10.1002/psp4.12291.
- Nikolopoulou E, Johnson L, Harris D, Nagy J, Stites E, Kuang Y. Tumour-immune dynamics with an immune checkpoint inhibitor. Letters In Biomathematics 2018, 5: s137-s159. DOI: 10.1080/23737867.2018.1440978.
- Nikolopoulou E, Johnson L, Harris D, Nagy J, Stites E, Kuang Y. Tumour-Immune Dynamics with an Immune Checkpoint Inhibitor. Letters In Biomathematics 2018, 5 DOI: 10.30707/lib5.2nikolopoulou.
- Ramanathan R, Weiss G, Posner R, Rajeshkumar N, Jameson G, Aziz M, Hoering A, Bolejack V, Maitra A, Fulk M, Stites E, Hlavacek W, Gatalica Z, Xiu J, Hidalgo M, Von Hoff D, Barrett M. A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients. Journal Of Gastrointestinal Oncology 2017, 8: 925-935. PMID: 29299351, PMCID: PMC5750179, DOI: 10.21037/jgo.2017.09.05.
- Stites E, Aziz M, Creamer M, Von Hoff D, Posner R, Hlavacek W. Use of Mechanistic Models to Integrate and Analyze Multiple Proteomic Datasets. Biophysical Journal 2015, 108: 1819-1829. PMID: 25863072, PMCID: PMC4390817, DOI: 10.1016/j.bpj.2015.02.030.
- Stites E, Trampont P, Haney L, Walk S, Ravichandran K. Cooperation between Noncanonical Ras Network Mutations. Cell Reports 2015, 10: 840. PMID: 30849858, DOI: 10.1016/j.celrep.2015.01.048.
- Stites E, Trampont P, Haney L, Walk S, Ravichandran K. Cooperation between Noncanonical Ras Network Mutations. Cell Reports 2015, 10: 307-316. PMID: 25600866, PMCID: PMC4503519, DOI: 10.1016/j.celrep.2014.12.035.
- Stites E, Trampont P, Haney L, Walk S, Ravichandran K. Abstract PR04: Cooperation between Ras network mutations in cancer. Molecular Cancer Research 2014, 12: pr04-pr04. DOI: 10.1158/1557-3125.rasonc14-pr04.
- Hu J, Stites E, Yu H, Germino E, Meharena H, Stork P, Kornev A, Taylor S, Shaw A. Allosteric Activation of Functionally Asymmetric RAF Kinase Dimers. Cell 2013, 154: 1036-1046. PMID: 23993095, PMCID: PMC3844432, DOI: 10.1016/j.cell.2013.07.046.
- Stites E. Chemical kinetic mechanistic models to investigate cancer biology and impact cancer medicine. Physical Biology 2013, 10: 026004. PMID: 23406820, DOI: 10.1088/1478-3975/10/2/026004.
- Chylek L, Stites E, Posner R, Hlavacek W. Innovations of the Rule-Based Modeling Approach. 2013, 273-300. DOI: 10.1007/978-94-007-6803-1_9.
- Stites E. The Response of Cancers to BRAF Inhibition Underscores the Importance of Cancer Systems Biology. Science Signaling 2012, 5: pe46. PMID: 23074264, DOI: 10.1126/scisignal.2003354.
- Liang W, Craig D, Carpten J, Borad M, Demeure M, Weiss G, Izatt T, Sinari S, Christoforides A, Aldrich J, Kurdoglu A, Barrett M, Phillips L, Benson H, Tembe W, Braggio E, Kiefer J, Legendre C, Posner R, Hostetter G, Baker A, Egan J, Han H, Lake D, Stites E, Ramanathan R, Fonseca R, Stewart A, Von Hoff D. Genome-Wide Characterization of Pancreatic Adenocarcinoma Patients Using Next Generation Sequencing. PLOS ONE 2012, 7: e43192. PMID: 23071490, PMCID: PMC3468610, DOI: 10.1371/journal.pone.0043192.
- Creamer M, Stites E, Aziz M, Cahill J, Tan C, Berens M, Han H, Bussey K, Von Hoff D, Hlavacek W, Posner R. Specification, annotation, visualization and simulation of a large rule-based model for ERBB receptor signaling. BMC Systems Biology 2012, 6: 107. PMID: 22913808, PMCID: PMC3485121, DOI: 10.1186/1752-0509-6-107.
- Abstract PR7: Clonal profiling of prospectively collected primary pancreatic ductal adenocarcinomas.Barrett M, Lenkiewicz E, Evers L, Holley T, Aziz M, Stites E, Posner R, Kramer A, Drebin J, Hoff D. Abstract PR7: Clonal profiling of prospectively collected primary pancreatic ductal adenocarcinomas. 2012, pr7-pr7. DOI: 10.1158/1538-7445.panca2012-pr7.
- Stites E, Ravichandran K. Mathematical Investigation of How Oncogenic Ras Mutants Promote Ras Signaling. Methods In Molecular Biology 2012, 880: 69-85. PMID: 23361982, DOI: 10.1007/978-1-61779-833-7_5.
- Liang W, Craig D, Carpten J, Borad M, Demeure M, Weiss G, Kiefer J, Posner R, Hostetter G, Izatt T, Sinari S, Christoforides A, Aldrich J, Kurdoglu A, Phillips L, Benson H, Baker A, Han H, Lake D, Stites E, Ramanathan R, Fonseca R, Stewart A, Hoff D. Abstract 5104: Identification of key tumorigenic pathways in pancreatic adenocarcinoma patients using massively parallel DNA and RNA sequencing. Cancer Research 2012, 72: 5104-5104. DOI: 10.1158/1538-7445.am2012-5104.
- Ramanathan R, Barrett M, Weiss G, Posner R, NV R, Jameson G, Demeure M, Hoering A, Stites E, Maitra A, Fulk M, Hidalgo M, Von Hoff D. Abstract LB-221: Phase II study of therapy selected by molecular profiling in patients with previously treated metastatic pancreatic cancer. A study of the stand up to cancer (SU2C) consortium. Cancer Research 2012, 72: lb-221-lb-221. DOI: 10.1158/1538-7445.am2012-lb-221.
- Barrett M, Lenkiewicz E, Evers L, Holley T, Aziz M, Kiefer J, Maitra A, Hidalgo M, Kumar R, Hlavacek W, Stites E, Posner R, Ramanathan R, Von Hoff D. Abstract 3697: Phase II study of therapy selected by molecular profiling in patients with previously treated metastatic pancreatic cancer - SU2C-001. Cancer Research 2012, 72: 3697-3697. DOI: 10.1158/1538-7445.am2012-3697.
- Stites E, Creamer M, Aziz M, Hlavacek W, Posner R. Large Scale, High Resolution Models of Receptor Tyrosine Kinase Signaling Networks. Biophysical Journal 2012, 102: 513a-514a. DOI: 10.1016/j.bpj.2011.11.2812.
- Stites E, Ravichandran K. Mechanistic modeling to investigate signaling by oncogenic Ras mutants. WIREs Mechanisms Of Disease 2011, 4: 117-127. PMID: 21766467, DOI: 10.1002/wsbm.156.
- Stites E. Modeling Membrane Localization: Case Study of a Ras Signaling Model. Advances In Experimental Medicine And Biology 2010, 680: 661-667. PMID: 20865552, DOI: 10.1007/978-1-4419-5913-3_73.
- Stites E, Ravichandran K. A Systems Perspective of Ras Signaling in Cancer. Clinical Cancer Research 2009, 15: 1510-1513. PMID: 19208795, DOI: 10.1158/1078-0432.ccr-08-2753.
- Stites E, Trampont P, Ma Z, Ravichandran K. Network Analysis of Oncogenic Ras Activation in Cancer. Science 2007, 318: 463-467. PMID: 17947584, DOI: 10.1126/science.1144642.
Departments and Programs
Biography
Edward Stites, MD, PhD, is a laboratory medicine specialist who applies both experimental and computational methods to diagnose and study diseases, with a particular focus on cancer.
Dr. Stites investigates how certain proteins, known as RAS proteins, help control cell growth and may contribute to tumor development. As an associate professor of laboratory medicine at Yale School of Medicine, he explores mathematical approaches to better understand disease processes.
He completed his medical training from the University of Virginia and pursued residency in pathology at Washington University School of Medicine.
Titles
- Associate Professor of Laboratory Medicine and Pathology
Education & Training
- Postdoctoral FellowWashington University School of Medicine (2016)
- ResidentWashington University School of Medicine (2015)
- Randy Pausch ScholarTranslational Genomics Research Institution (2012)
- MDUniversity of Virginia (2010)
- PhDUniversity of Virginia, Biophysics (2008)
- BSUniversity of Kentucky, Mathematics (1998)
Additional Information
Honors & Recognitions
- New Innovator Award (DP2): National Institutes of Health Director's Common Fund (2020)
- Career Development Award: Department of Defense (2020)
- Lung Cancer Discovery Award: American Lung Association (2020)
- Young Investigator Award: Melanoma Research Alliance (2018)
- Career Development Award: National Cancer Institute (2017)
Professional Service
- Forbeck Foundation (2024 - Present): Member
Publications
- Arun A, Liarakos D, Mendiratta G, Kim J, Goshua G, Olson P, Stites E. Integrating epidemiology and genomics data to estimate the prevalence of acquired cysteine drug targets in the U.S. cancer patient population. The Pharmacogenomics Journal 2025, 25: 5. PMID: 40044654, DOI: 10.1038/s41397-025-00364-3.
- Trogdon M, Abbott K, Arang N, Lande K, Kaur N, Tong M, Bakhoum M, Gutkind J, Stites E. Systems modeling of oncogenic G-protein and GPCR signaling reveals unexpected differences in downstream pathway activation. Npj Systems Biology And Applications 2024, 10: 75. PMID: 39013872, PMCID: PMC11252164, DOI: 10.1038/s41540-024-00400-1.
- Mendiratta G, Liarakos D, Tong M, Ito S, Ke E, Goshua G, Stites E. Cancer research is not correlated with driver gene mutation burdens. Med 2024, 5: 832-838.e4. PMID: 38908369, DOI: 10.1016/j.medj.2024.05.013.
- Stites E. The Abundance of KRAS and RAS Gene Mutations in Cancer. Methods In Molecular Biology 2024, 2797: 13-22. PMID: 38570449, DOI: 10.1007/978-1-0716-3822-4_2.
- Ito S, Pandya A, Hauser R, Krishnamurti L, Stites E, Tormey C, Krumholz H, Hendrickson J, Goshua G. Decreasing alloimmunization‐specific mortality in sickle cell disease in the United States: Cost‐effectiveness of a shared transfusion resource. American Journal Of Hematology 2024, 99: 570-576. PMID: 38279581, DOI: 10.1002/ajh.27211.
- Mendiratta G, Stites E. Theoretical analysis reveals a role for RAF conformational autoinhibition in paradoxical activation. ELife 2023, 12: e82739. PMID: 37823369, PMCID: PMC10627510, DOI: 10.7554/elife.82739.
- Baglaenko Y, Wagner C, Bhoj V, Brodin P, Gershwin M, Graham D, Invernizzi P, Kidd K, Korsunsky I, Levy M, Mammen A, Nizet V, Ramirez-Valle F, Stites E, Williams M, Wilson M, Rose N, Ladd V, Sirota M. Making inroads to precision medicine for the treatment of autoimmune diseases: Harnessing genomic studies to better diagnose and treat complex disorders. Cambridge Prisms Precision Medicine 2023, 1: e25. PMID: 38550937, PMCID: PMC10953750, DOI: 10.1017/pcm.2023.14.
- Stites E. Computational Random Mutagenesis to Investigate RAS Mutant Signaling. Methods In Molecular Biology 2023, 2634: 329-335. PMID: 37074586, PMCID: PMC10530643, DOI: 10.1007/978-1-0716-3008-2_15.
- McFall T, Trogdon M, Guizar A, Langenheim J, Sisk-Hackworth L, Stites E. Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP. Npj Precision Oncology 2022, 6: 86. PMID: 36418474, PMCID: PMC9684405, DOI: 10.1038/s41698-022-00329-w.
- Stites E, Paskvan K, Kato S. Therapeutic Targeting of RAS Mutant Cancers. 2022 DOI: 10.1017/9781009064828.
- Mendiratta G, Jones M, Stites E. How often is each gene mutated within the cancer patient population? Molecular & Cellular Oncology 2022, 9: 2065176. PMID: 35529901, PMCID: PMC9067461, DOI: 10.1080/23723556.2022.2065176.
- McFall T, Stites E. Identification of RAS mutant biomarkers for EGFR inhibitor sensitivity using a systems biochemical approach. Cell Reports 2021, 37: 110096. PMID: 34910921, PMCID: PMC8867612, DOI: 10.1016/j.celrep.2021.110096.
- Mendiratta G, Ke E, Aziz M, Liarakos D, Tong M, Stites E. Cancer gene mutation frequencies for the U.S. population. Nature Communications 2021, 12: 5961. PMID: 34645806, PMCID: PMC8514428, DOI: 10.1038/s41467-021-26213-y.
- Stites E. Mathematical Modeling to Study KRAS Mutant-Specific Responses to Pathway Inhibition. Methods In Molecular Biology 2021, 2262: 311-321. PMID: 33977486, PMCID: PMC8639139, DOI: 10.1007/978-1-0716-1190-6_19.
- Kato S, McFall T, Takahashi K, Bamel K, Ikeda S, Eskander R, Plaxe S, Parker B, Stites E, Kurzrock R. KRAS‐Mutated, Estrogen Receptor‐Positive Low‐Grade Serous Ovarian Cancer: Unraveling an Exceptional Response Mystery. The Oncologist 2021, 26: e530-e536. PMID: 33528846, PMCID: PMC8018312, DOI: 10.1002/onco.13702.
- McFall T, Schomburg N, Rossman K, Stites E. Discernment between candidate mechanisms for KRAS G13D colorectal cancer sensitivity to EGFR inhibitors. Cell Communication And Signaling 2020, 18: 179. PMID: 33153459, PMCID: PMC7643456, DOI: 10.1186/s12964-020-00645-3.
- Kato S, Kim K, Lim H, Boichard A, Nikanjam M, Weihe E, Kuo D, Eskander R, Goodman A, Galanina N, Fanta P, Schwab R, Shatsky R, Plaxe S, Sharabi A, Stites E, Adashek J, Okamura R, Lee S, Lippman S, Sicklick J, Kurzrock R. Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy. Nature Communications 2020, 11: 4965. PMID: 33009371, PMCID: PMC7532150, DOI: 10.1038/s41467-020-18613-3.
- Stites EC, Wilen CB. The Interpretation of SARS-CoV-2 Diagnostic Tests. Med 2020, 1: 78-89. PMID: 32864639, PMCID: PMC7441939, DOI: 10.1016/j.medj.2020.08.001.
- Mendiratta G, McFall T, Stites E. Abstract 5509: Breaking the paradox breakers - RAF inhibitor mechanisms. Cancer Research 2020, 80: 5509-5509. DOI: 10.1158/1538-7445.am2020-5509.
- McFall T, Stites E. Abstract 37: Computational analysis of the KRAS G13D colorectal cancer response to EGFR inhibition with an alternatively parameterized model. Clinical Cancer Research 2020, 26: 37-37. DOI: 10.1158/1557-3265.advprecmed20-37.
- Stites E, McFall T. A Biophysical Basis for a Targeted Therapy Exceptional Responder KRAS Mutation. Biophysical Journal 2020, 118: 451a. DOI: 10.1016/j.bpj.2019.11.2515.
- McFall T, Stites E. A mechanism for the response of KRASG13D expressing colorectal cancers to EGFR inhibitors. Molecular & Cellular Oncology 2020, 7: 1701914. PMID: 32158916, PMCID: PMC7051129, DOI: 10.1080/23723556.2019.1701914.
- McFall T, Diedrich J, Mengistu M, Littlechild S, Paskvan K, Sisk-Hackworth L, Moresco J, Shaw A, Stites E. A systems mechanism for KRAS mutant allele–specific responses to targeted therapy. Science Signaling 2019, 12 PMID: 31551296, PMCID: PMC6864030, DOI: 10.1126/scisignal.aaw8288.
- Erickson KE, Rukhlenko OS, Shahinuzzaman M, Slavkova KP, Lin YT, Suderman R, Stites EC, Anghel M, Posner RG, Barua D, Kholodenko BN, Hlavacek WS. Modeling cell line-specific recruitment of signaling proteins to the insulin-like growth factor 1 receptor. PLOS Computational Biology 2019, 15: e1006706. PMID: 30653502, PMCID: PMC6353226, DOI: 10.1371/journal.pcbi.1006706.
- Rauen K, Schoyer L, Schill L, Stronach B, Albeck J, Andresen B, Cavé H, Ellis M, Fruchtman S, Gelb B, Gibson C, Gripp K, Hefner E, Huang W, Itkin M, Kerr B, Linardic C, McMahon M, Oberlander B, Perlstein E, Ratner N, Rogers L, Schenck A, Shankar S, Shvartsman S, Stevenson D, Stites E, Stork P, Sun C, Therrien M, Ullian E, Widemann B, Yeh E, Zampino G, Zenker M, Timmer W, McCormick F. Proceedings of the fifth international RASopathies symposium: When development and cancer intersect. American Journal Of Medical Genetics Part A 2018, 176: 2924-2929. PMID: 30302932, PMCID: PMC6312476, DOI: 10.1002/ajmg.a.40632.
- Stites E, Shaw A. Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors. CPT Pharmacometrics & Systems Pharmacology 2018, 7: 342-351. PMID: 29484842, PMCID: PMC5980551, DOI: 10.1002/psp4.12291.
- Nikolopoulou E, Johnson L, Harris D, Nagy J, Stites E, Kuang Y. Tumour-immune dynamics with an immune checkpoint inhibitor. Letters In Biomathematics 2018, 5: s137-s159. DOI: 10.1080/23737867.2018.1440978.
- Nikolopoulou E, Johnson L, Harris D, Nagy J, Stites E, Kuang Y. Tumour-Immune Dynamics with an Immune Checkpoint Inhibitor. Letters In Biomathematics 2018, 5 DOI: 10.30707/lib5.2nikolopoulou.
- Ramanathan R, Weiss G, Posner R, Rajeshkumar N, Jameson G, Aziz M, Hoering A, Bolejack V, Maitra A, Fulk M, Stites E, Hlavacek W, Gatalica Z, Xiu J, Hidalgo M, Von Hoff D, Barrett M. A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients. Journal Of Gastrointestinal Oncology 2017, 8: 925-935. PMID: 29299351, PMCID: PMC5750179, DOI: 10.21037/jgo.2017.09.05.
- Stites E, Aziz M, Creamer M, Von Hoff D, Posner R, Hlavacek W. Use of Mechanistic Models to Integrate and Analyze Multiple Proteomic Datasets. Biophysical Journal 2015, 108: 1819-1829. PMID: 25863072, PMCID: PMC4390817, DOI: 10.1016/j.bpj.2015.02.030.
- Stites E, Trampont P, Haney L, Walk S, Ravichandran K. Cooperation between Noncanonical Ras Network Mutations. Cell Reports 2015, 10: 840. PMID: 30849858, DOI: 10.1016/j.celrep.2015.01.048.
- Stites E, Trampont P, Haney L, Walk S, Ravichandran K. Cooperation between Noncanonical Ras Network Mutations. Cell Reports 2015, 10: 307-316. PMID: 25600866, PMCID: PMC4503519, DOI: 10.1016/j.celrep.2014.12.035.
- Stites E, Trampont P, Haney L, Walk S, Ravichandran K. Abstract PR04: Cooperation between Ras network mutations in cancer. Molecular Cancer Research 2014, 12: pr04-pr04. DOI: 10.1158/1557-3125.rasonc14-pr04.
- Hu J, Stites E, Yu H, Germino E, Meharena H, Stork P, Kornev A, Taylor S, Shaw A. Allosteric Activation of Functionally Asymmetric RAF Kinase Dimers. Cell 2013, 154: 1036-1046. PMID: 23993095, PMCID: PMC3844432, DOI: 10.1016/j.cell.2013.07.046.
- Stites E. Chemical kinetic mechanistic models to investigate cancer biology and impact cancer medicine. Physical Biology 2013, 10: 026004. PMID: 23406820, DOI: 10.1088/1478-3975/10/2/026004.
- Chylek L, Stites E, Posner R, Hlavacek W. Innovations of the Rule-Based Modeling Approach. 2013, 273-300. DOI: 10.1007/978-94-007-6803-1_9.
- Stites E. The Response of Cancers to BRAF Inhibition Underscores the Importance of Cancer Systems Biology. Science Signaling 2012, 5: pe46. PMID: 23074264, DOI: 10.1126/scisignal.2003354.
- Liang W, Craig D, Carpten J, Borad M, Demeure M, Weiss G, Izatt T, Sinari S, Christoforides A, Aldrich J, Kurdoglu A, Barrett M, Phillips L, Benson H, Tembe W, Braggio E, Kiefer J, Legendre C, Posner R, Hostetter G, Baker A, Egan J, Han H, Lake D, Stites E, Ramanathan R, Fonseca R, Stewart A, Von Hoff D. Genome-Wide Characterization of Pancreatic Adenocarcinoma Patients Using Next Generation Sequencing. PLOS ONE 2012, 7: e43192. PMID: 23071490, PMCID: PMC3468610, DOI: 10.1371/journal.pone.0043192.
- Creamer M, Stites E, Aziz M, Cahill J, Tan C, Berens M, Han H, Bussey K, Von Hoff D, Hlavacek W, Posner R. Specification, annotation, visualization and simulation of a large rule-based model for ERBB receptor signaling. BMC Systems Biology 2012, 6: 107. PMID: 22913808, PMCID: PMC3485121, DOI: 10.1186/1752-0509-6-107.
- Abstract PR7: Clonal profiling of prospectively collected primary pancreatic ductal adenocarcinomas.Barrett M, Lenkiewicz E, Evers L, Holley T, Aziz M, Stites E, Posner R, Kramer A, Drebin J, Hoff D. Abstract PR7: Clonal profiling of prospectively collected primary pancreatic ductal adenocarcinomas. 2012, pr7-pr7. DOI: 10.1158/1538-7445.panca2012-pr7.
- Stites E, Ravichandran K. Mathematical Investigation of How Oncogenic Ras Mutants Promote Ras Signaling. Methods In Molecular Biology 2012, 880: 69-85. PMID: 23361982, DOI: 10.1007/978-1-61779-833-7_5.
- Liang W, Craig D, Carpten J, Borad M, Demeure M, Weiss G, Kiefer J, Posner R, Hostetter G, Izatt T, Sinari S, Christoforides A, Aldrich J, Kurdoglu A, Phillips L, Benson H, Baker A, Han H, Lake D, Stites E, Ramanathan R, Fonseca R, Stewart A, Hoff D. Abstract 5104: Identification of key tumorigenic pathways in pancreatic adenocarcinoma patients using massively parallel DNA and RNA sequencing. Cancer Research 2012, 72: 5104-5104. DOI: 10.1158/1538-7445.am2012-5104.
- Ramanathan R, Barrett M, Weiss G, Posner R, NV R, Jameson G, Demeure M, Hoering A, Stites E, Maitra A, Fulk M, Hidalgo M, Von Hoff D. Abstract LB-221: Phase II study of therapy selected by molecular profiling in patients with previously treated metastatic pancreatic cancer. A study of the stand up to cancer (SU2C) consortium. Cancer Research 2012, 72: lb-221-lb-221. DOI: 10.1158/1538-7445.am2012-lb-221.
- Barrett M, Lenkiewicz E, Evers L, Holley T, Aziz M, Kiefer J, Maitra A, Hidalgo M, Kumar R, Hlavacek W, Stites E, Posner R, Ramanathan R, Von Hoff D. Abstract 3697: Phase II study of therapy selected by molecular profiling in patients with previously treated metastatic pancreatic cancer - SU2C-001. Cancer Research 2012, 72: 3697-3697. DOI: 10.1158/1538-7445.am2012-3697.
- Stites E, Creamer M, Aziz M, Hlavacek W, Posner R. Large Scale, High Resolution Models of Receptor Tyrosine Kinase Signaling Networks. Biophysical Journal 2012, 102: 513a-514a. DOI: 10.1016/j.bpj.2011.11.2812.
- Stites E, Ravichandran K. Mechanistic modeling to investigate signaling by oncogenic Ras mutants. WIREs Mechanisms Of Disease 2011, 4: 117-127. PMID: 21766467, DOI: 10.1002/wsbm.156.
- Stites E. Modeling Membrane Localization: Case Study of a Ras Signaling Model. Advances In Experimental Medicine And Biology 2010, 680: 661-667. PMID: 20865552, DOI: 10.1007/978-1-4419-5913-3_73.
- Stites E, Ravichandran K. A Systems Perspective of Ras Signaling in Cancer. Clinical Cancer Research 2009, 15: 1510-1513. PMID: 19208795, DOI: 10.1158/1078-0432.ccr-08-2753.
- Stites E, Trampont P, Ma Z, Ravichandran K. Network Analysis of Oncogenic Ras Activation in Cancer. Science 2007, 318: 463-467. PMID: 17947584, DOI: 10.1126/science.1144642.
Departments and Programs